Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics-Reference-Cited by-同舟云学术

Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics

Published:2019-04 Issue:4 Volume:108 Page:1442-1452
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Kretsinger Juliana,Frantz Neha,Hart Scott A.,Kelley Wayne P.,Kitchen Bob,Novick Shawn,Rellahan Barbara,Stranges Daniela,Stroop Corné J.M.,Yin Ping,Gastens Martin H.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference7 articles.

1. Specifications: Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products,1999

2. Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Procedures Chemical Substances,1999

3. Early development GMPs for small-molecule specifications: an industry perspective (part V);Zhang;Pharm Technol,2012

4. PCMO L01-setting specifications for biological investigational medicinal products;Krause;PDA J Pharm Sci Technol,2015

5. The Challenge of CMC Regulatory Compliance for Biopharmaceuticals;Geigert,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High performance production process development and scale-up of an anti-TSLP nanobody;Protein Expression and Purification;2024-06

2. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics;J PHARM ANAL;2024

3. Patient-Centric Quality Standards;Journal of Pharmaceutical Sciences;2024-04

4. CE methods for charge variant analysis of mAbs and complex format biotherapeutics;ELECTROPHORESIS;2024-01-17

5. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations;International Journal of Pharmaceutics: X;2023-12